financetom
Business
financetom
/
Business
/
BRIEF-Miami International Says Wellington Management Indicated Interest To Buy Up To $40 Million In Common Shares In IPO At IPO Price
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRIEF-Miami International Says Wellington Management Indicated Interest To Buy Up To $40 Million In Common Shares In IPO At IPO Price
Aug 4, 2025 6:37 AM

Aug 4 (Reuters) - Miami International Holdings Inc

:

* MIAMI INTERNATIONAL HOLDINGS INC SAYS ESTIMATED IPO PRICE

WILL

BE BETWEEN $19.00 AND $21.00 PER SHARE - SEC FILING

* MIAMI INTERNATIONAL HOLDINGS INC SEES IPO OF UP TO 15

MILLION

SHARES OF COMMON STOCK

* MIAMI INTERNATIONAL HOLDINGS - WELLINGTON MANAGEMENT

INDICATED

INTEREST TO BUY UP TO $40 MILLION IN COMMON SHARES IN IPO AT IPO

PRICE

* MIAMI INTERNATIONAL HOLDINGS SAYS IT ADDS ROSENBLATT AS AN

UNDERWRITER TO IPO

* MIAMI INTERNATIONAL HOLDINGS - TO USE PORTION OF IPO

PROCEEDS TO

REPAY IN FULL ALL OUTSTANDING INDEBTEDNESS UNDER 2029 SENIOR

SECURED LOAN AGREEMENT

Source text:

Further company coverage:

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AerCap Reports Q3 Asset Sales, Acquisitions, Lease Agreements
AerCap Reports Q3 Asset Sales, Acquisitions, Lease Agreements
Oct 7, 2024
08:13 AM EDT, 10/07/2024 (MT Newswires) -- AerCap ( AER ) , an aviation leasing company, said Monday that it completed 41 asset acquisitions, 25 asset sales, and signed 160 lease agreements during Q3. The acquisitions include 27 airplanes, 13 engines, and one helicopter. The sales include 18 airplanes, four helicopters, and three engines. And the lease agreements covered 107...
Intellia Therapeutics Launches Phase 3 Trial of Investigational Hereditary Angioedema Treatment
Intellia Therapeutics Launches Phase 3 Trial of Investigational Hereditary Angioedema Treatment
Oct 7, 2024
08:12 AM EDT, 10/07/2024 (MT Newswires) -- Intellia Therapeutics ( NTLA ) said Monday it has launched a global phase 3 trial to assess the efficacy and safety of NTLA-2002 in 60 adults with Type 1 or Type 2 hereditary angioedema. The trial's primary endpoint is the change in number of hereditary angioedema attacks from the fifth week to the...
Walgreens names Optum's Jason Stenta as chief commercial officer
Walgreens names Optum's Jason Stenta as chief commercial officer
Oct 7, 2024
Oct 7 (Reuters) - Pharmacy operator Walgreens Boots Alliance ( WBA ) named Jason Stenta as chief commercial officer on Monday. Stenta was hired from UnitedHealth's ( UNH ) unit, Optum. (Reporting by Puyaan Singh in Bengaluru; Editing by Anil D'Silva) ...
Lightspeed Names Retail Industry Veteran Chris Akrimi as Head of Revenue
Lightspeed Names Retail Industry Veteran Chris Akrimi as Head of Revenue
Oct 7, 2024
08:10 AM EDT, 10/07/2024 (MT Newswires) -- Lightspeed (LSPD.TO, LSPD), a B2B commerce platform, said on Monday that it appointed Chris Akrimi as head of revenue for Lightspeed B2B and NuORDER. Akrimi was most recently CEO at The Layer, a technology company transforming commerce data through artificial intelligence (AI), where he focused on positioning the company at the forefront of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved